Could a bone drug ease pain in kids with rare inflammatory disease?

NCT ID NCT07668583

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether the drug zoledronate can reduce pain in children aged 4 to 17 with chronic recurrent multifocal osteomyelitis (CRMO), a rare auto-inflammatory bone disease. The 30 participants have not responded to standard anti-inflammatory drugs. They will receive either zoledronate or a placebo by IV, and their pain levels will be tracked over 12 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

zoledronate (a bisphosphonate drug given by IV)

What this could lead to

If it works, this could point toward a new treatment option for children with hard-to-treat CRMO bone pain.

What could go wrong

This is a small early-phase trial with only 30 children, so results may not apply to everyone. The drug also has known risks like flu-like symptoms and kidney issues.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OSTEOMYELITIS CHRONIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic recurrent multifocal osteomyelitis osteomyelitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Kremlin-Bicêtre Hospital

    Le Kremlin-Bicêtre, Val De Marne, 94270, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••